For the first time, the Union Cycliste Internationale (UCI), Cycling Anti-Doping Foundation (CADF) and U.S. Anti-Doping Agency (USADA) will collaborate to conduct in- and out-of-competition drug testing.
The partnership is centered on anti-doping efforts at the Amgen Tour of California. Collaboration between anti-doping stakeholders has never come easy, despite a common goal. The Tour of California partnership, announced Saturday, reflects a number of recommendations made by the Cycling Independent Reform Commission (CIRC) report.
The three organizations will coordinate test distribution planning and sample collection. Samples will be screened for the usual substances and methods, including EPO, and certain samples will be selected for additional analysis. These samples will be tested for synthetic testosterone via the CIR test, as well as for CERA, a form of EPO, and human growth hormone.
The samples will also be applied to USADA and the UCI’s Biological Passport programs.
Urine and blood samples collected may be stored for up to ten years, so that in the event of new tested methods they can be re-evaluated. Re-testing was another recommendation of the CIRC report.
“Working closely with national anti-doping organizations is key part of the CADF’s long-term strategy for planning and implementing anti-doping testing programs in cycling,” said Francesca Rossi, director of the CADF.
“The UCI and the CADF’s willingness to work in partnership with national anti- doping organizations is a strong demonstration of the current UCI leadership’s commitment to moving the sport forward from the past, and we look forward to continuing to work with them in the future for the benefit of all clean athletes,” said USADA CEO Travis T. Tygart.
“This agreement with USADA for the 2015 Amgen Tour of California is a new important step forward after previous collaborations set with NADOs from Switzerland, France, and the UK among others,” said UCI President Brian Cookson.